Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-AraG PET/CT for Chemoradiation Treatment Response in Esophageal Cancer
NCT06414902Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorine f 18 ara-g in esophageal cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Sep 2024; status: recruiting.
02
Drugs
fluorine f 18 ara-g
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT06414902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414902.